Filing Details

Accession Number:
0001062993-20-004556
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-17 17:07:04
Reporting Period:
2020-09-15
Accepted Time:
2020-09-17 17:07:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
819050 Brickell Biotech Inc. BBI Biological Products, (No Disgnostic Substances) (2836) 930948554
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1225341 T Dennison Veru C/o Brickell Biotech, Inc.
5777 Central Avenue, Suite 102
Boulder CO 80301
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-09-14 19,642 $0.00 7,230 No 5 G Direct
Common Stock Acquisiton 2020-09-15 13,580 $0.81 20,810 No 4 A Direct
Common Stock Acquisiton 2020-09-15 15,355 $0.81 36,165 No 4 P Direct
Common Stock Acquisiton 2020-09-16 14,645 $0.80 50,810 No 4 P Direct
Common Stock Acquisiton 2020-09-14 19,642 $0.00 980,030 No 5 G Indirect By self due to Control over the Entity that holds Shares
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Direct
No 4 A Direct
No 4 P Direct
No 4 P Direct
No 5 G Indirect By self due to Control over the Entity that holds Shares
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2020-09-15 60,000 $0.00 60,000 $0.80
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
60,000 2030-09-15 No 4 A Direct
Footnotes
  1. On September 15, 2020, the reporting person was granted 13,580 restricted stock units ("RSUs") in lieu of a portion of cash compensation as a director of Brickell Biotech, Inc. The RSUs are scheduled to vest on December 31, 2020 and will be settled in the form of one share of common stock for each RSU.
  2. Represents the purchase of 15,355 shares in multiple transactions, ranging in price from $0.80 to $0.8153 per share, resulting in a weighted average purchase price of $0.8086. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each price within the range.
  3. Represents the purchase of 14,645 shares in multiple transactions, ranging in price from $0.80 to $0.81 per share, resulting in a weighted average purchase price of $0.8029. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each price within the range.
  4. The stock options will vest 25% on September 15, 2021, and the remainder will vest in equal monthly installments over the following three years.